213 related articles for article (PubMed ID: 24486603)
21. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
22. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
[TBL] [Abstract][Full Text] [Related]
23. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
[TBL] [Abstract][Full Text] [Related]
24. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
26. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
27. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
28. Y-box binding protein, YB-1, as a marker of tumor aggressiveness and response to adjuvant chemotherapy in breast cancer.
Huang J; Tan PH; Li KB; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2005 Mar; 26(3):607-13. PubMed ID: 15703814
[TBL] [Abstract][Full Text] [Related]
29. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
30. Clusterin expression predicts survival of invasive cervical cancer patients treated with radical hysterectomy and systematic lymphadenectomy.
Watari H; Ohta Y; Hassan MK; Xiong Y; Tanaka S; Sakuragi N
Gynecol Oncol; 2008 Mar; 108(3):527-32. PubMed ID: 18177691
[TBL] [Abstract][Full Text] [Related]
31. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
32. High expression of Y-box-binding protein-1 is associated with poor survival in resectable esophageal squamous cell carcinoma.
Li Y; Wen ZS; Yang HX; Luo RZ; Zhang Y; Zhang MF; Wang X; Jia WH
Ann Surg Oncol; 2011 Nov; 18(12):3370-6. PubMed ID: 21630125
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of nuclear factor κ B expression in patients with advanced cervical cancer undergoing radiation therapy followed by hysterectomy.
Baiocchi G; Begnami MD; Fukazawa EM; Oliveira RA; Faloppa CC; Kumagai LY; Badiglian-Filho L; Pellizzon AC; Maia MA; Jacinto AA; Soares FA; Lopes A
J Clin Pathol; 2012 Jul; 65(7):614-8. PubMed ID: 22447917
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
35. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
38. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
[TBL] [Abstract][Full Text] [Related]
39. Y-box binding protein 1 is correlated with lymph node metastasis in intestinal-type gastric cancer.
Guo T; Yu Y; Yip GW; Baeg GH; Thike AA; Lim TK; Tan PH; Matsumoto K; Bay BH
Histopathology; 2015 Mar; 66(4):491-9. PubMed ID: 25270600
[TBL] [Abstract][Full Text] [Related]
40. High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer.
Yan X; Yan L; Zhou J; Liu S; Shan Z; Jiang C; Tian Y; Jin Z
Int J Clin Exp Pathol; 2014; 7(12):8715-23. PubMed ID: 25674237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
